Search

Displaying results 31 - 40 of 368 in total
  1. Drug

    Indapamide

    go.drugbank.com/drugs/DB00808
    ApprovedInvestigational

    , lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. … [A204134] When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index

  2. Drug

    Unoprostone

    go.drugbank.com/drugs/DB06826
    ApprovedWithdrawn

    Unoprostone isopropyl is a prostaglandin analogue. Ophthalmic Solution 0.15% is a synthetic docosanoid. Unoprostone isopropyl has the chemical name isopropyl (+)-(Z)-7-[(1R,2R,3R,5S)-3,5 dihydroxy-2-(3-oxodecyl)cyclopentyl]-5-heptenoate....

  3. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    Evinacumab is novel in its mechanism of action compared with other lipid-lowering therapies and therefore provides a unique and synergistic therapeutic option in the treatment of HoFH.

  4. Drug

    Glymidine

    go.drugbank.com/drugs/DB01382
    Approved

    The mechanism of action of glycodiazine in lowering blood glucose appears to be dependent on stimulating the release of insulin from functioning pancreatic beta cells, and increasing sensitivity of peripheral

    Categories: Blood Glucose Lowering Agents
  5. Drug

    Mipomersen

    go.drugbank.com/drugs/DB05528
    Approved

    Mipomersen is indicated in patients with homozygous familial hypercholesterolemia as an adjunct to diet and other lipid-lowering medications.

  6. Drug

    Ivabradine

    go.drugbank.com/drugs/DB09083
    ApprovedInvestigational

    Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. … Therefore, as ivabradine is designed as a "pure" heart rate-lowering drug by selectively acting on the If channels, it may offer a more favorable side effect profile due to its lower likelihood of causing

  7. Drug

    Volanesorsen

    go.drugbank.com/drugs/DB15067
    Approved

    [L16621] This drug is not commonly prescribed as it is used as an adjunct to diet in patients at high risk for pancreatitis, who have had inadequate response to triglyceride lowering therapy.

  8. Drug

    Ezetimibe

    go.drugbank.com/drugs/DB00973
    ApprovedInvestigational

    Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption.

    Mixtures: EZETIMIBE E SIMVASTATINA ALMUS, EZETIMIBE E SIMVASTATINA ALMUSProducts: EZETIMIBE ALMUS
  9. Drug

    Inclisiran

    go.drugbank.com/drugs/DB14901
    ApprovedInvestigational

    [A225953,A225958] Lowering circulating plasma LDL-C levels offers an additional benefit of reducing the risk of cardiovascular disease (CVD) and improving cardiovascular outcomes, as hypercholesterolemia … first and only approved siRNA for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia, alone or in combination with other lipid-lowering

  10. Drug

    Nipocalimab

    go.drugbank.com/drugs/DB16257
    ApprovedInvestigational

    [L64042] It is an aglycosylated, fully human IgG1 monoclonal antibody that binds FcRn and blocks the receptor's recycling of immunoglobulin G (IgG), thereby lowering circulating IgG levels, including pathogenic